Novonesis consensus picture on Copenhagen, shares trade around 55 euros

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 14:12.

Novonesis (DK0060336014) sits in the European biotech segment with a steady valuation profile today. The shares trade near 55 euros on the Stuttgart venue in euro terms, giving the group a market capitalization of around 22.5 billion euros according to a German quote service.

What the consensus data show

The Novonesis B shares carry the ticker NSIS B on Nordic exchanges and NZM2 on German trading systems, anchoring the stock in the broader European biotech peer group that includes names such as Novo Nordisk and Novartis. A German data provider reports a last Stuttgart quote of 55.02 euros this morning, with a small intraday range and limited trading volume.

Based on the same data set, Novonesis shows earnings per share of 1.25, 1.56 and 1.82 euros over the past three reporting years, with the corresponding price-earnings ratios dropping from 43.62 to 34.92 and then 29.93. The reported dividend climbed from 0.87 to 0.95 and then 1.04 euros per share, translating into a dividend yield between roughly 1.6 and 1.9 percent at recent prices.

Analyst focus on valuation

The free float in Novonesis stands at just over 60 percent, with Novo Holdings and a roster of institutional investors including Norges Bank and BlackRock among the main identified shareholders. That ownership structure gives analysts a relatively stable base when they model earnings and dividend growth for the Copenhagen-listed group, even as broader biotech valuations fluctuate.

At a market capitalization of close to 22.5 billion euros and a dividend yield below 2 percent, Novonesis trades at a premium to some smaller biotech peers but in line with larger high-margin ingredient producers. The combination of mid-teen earnings growth, a gradual dividend increase and solid free float has kept the stock on the radar of European equity research desks, though detailed rating splits and price targets are not always publicly disclosed in real time.

The product behind the stock

Novonesis generates most of its revenue from industrial enzymes and microbes used in food, agriculture, household care and bioenergy applications. A flagship baking solution is Novamyl, an enzyme line that slows starch retrogradation in sliced bread and helps keep the crumb soft and springy for longer shelf life.

Where the stock trades today

Novonesis shares (ISIN DK0060336014) trade on 2026-06-30 at 06:04 on Stuttgart at 55.02 euros, based on the latest available German quotation in euro terms.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, recommendations or solicitation to buy or sell securities. All data are based on sources deemed reliable at the time of publication but may change without notice.